Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

Rhea-AI Summary

Clearside Biomedical (Nasdaq: CLSD) announced that its Chief Medical Officer, Thomas A. Ciulla, will present at the Needham Virtual Healthcare Conference on April 13, 2022, at 3:45 p.m. ET. The presentation will highlight Clearside's innovative approach to delivering therapies to the back of the eye through the suprachoroidal space (SCS).

For those interested, a live and archived webcast will be accessible on the Clearside website under the Investors section.

ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at the Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

What event is Clearside Biomedical participating in on April 13, 2022?

Clearside Biomedical will present at the Needham Virtual Healthcare Conference on April 13, 2022.

Who will present Clearside Biomedical's information at the Needham Conference?

Thomas A. Ciulla, M.D., MBA, the Chief Medical Officer and Chief Development Officer, will present.

What is the focus of Clearside Biomedical's presentation?

The presentation will focus on the delivery of therapies to the back of the eye via the suprachoroidal space.

How can I access the Clearside Biomedical presentation?

The live and archived webcast can be accessed on Clearside's website under the Investors section.

What is the stock symbol for Clearside Biomedical?

Clearside Biomedical is listed under the stock symbol CLSD.